WEKO3
-
RootNode
アイテム
Progressive hypofractionated carbon-ion radiotherapy for hepatocellular carcinoma: Combined analyses of 2 prospective trials
https://repo.qst.go.jp/records/48574
https://repo.qst.go.jp/records/4857451b1cc69-f3a7-4359-ba42-c23773a288d1
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2018-03-14 | |||||
| タイトル | ||||||
| タイトル | Progressive hypofractionated carbon-ion radiotherapy for hepatocellular carcinoma: Combined analyses of 2 prospective trials | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | journal article | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
Kasuya, Goro
× Kasuya, Goro× Katou, Hirotoshi× Yasuda, Shigeo× Tsuji, Hiroshi× Yamada, Shigeru× Haruyama, Yasuo× Kobashi, Gen× Ebner, Daniel× Okada, Naomi× Makishima, Hirokazu× Miyazaki, Masaru× Kamada, Tadashi× Tsujii, Hirohiko× 粕谷 吾朗× 加藤 博敏× 安田 茂雄× 辻 比呂志× 山田 滋× 春山 康夫× 小橋 元× エブナー ダニエル× 岡田 直美× 牧島 弘和× 宮崎 勝× 鎌田 正× 辻井 博彦 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | BACKGROUND: \nThe objective of this study was to evaluate the safety and efficacy of carbon-ion radiotherapy (CIRT) in patients with hepatocellular carcinoma (HCC) with stepwise dose escalation and hypofractionation in 2 combined prospective trials. \nMETHODS: \nSequential phase 1/2 (protocol 9603) and phase 2 (protocol 0004) trials were conducted for patients with histologically proven HCC. The phase 1 component of protocol 9603 was a dose-escalation study; CIRT was delivered in 12, 8, or 4 fractions. After determination of the recommended dose, 2 phase 2 trials were performed in an expanded cohort, and the data were pooled to analyze toxicity, local control, and overall survival. \nRESULTS: \nIn the phase 1 component of protocol 9603, 69.6, 58.0, and 52.8 Gy (relative biological effectiveness [RBE]) in 12, 8, and 4 fractions, respectively, constituted the maximum tolerated doses, and 52.8 Gy (RBE) in 4 fractions was established as the recommended dose regimen for the 2 phase 2 studies. In 124 patients with a total of 133 lesions, few severe adverse effects occurred, and local-control and overall survival rates at 1, 3, and 5 years were 94.7% and 90.3%, 91.4% and 50.0%, and 90.0% and 25.0%, respectively; this included 1-, 3-, and 5-year local-control rates of 97.8%, 95.5%, and 91.6%, respectively, in the phase 2 study. In a multivariate analysis, Child-Pugh class B and the presence of a tumor thrombus were significant factors for mortality. \nCONCLUSIONS: \nThe safety and efficacy of CIRT in 12, 8, and 4 fractions were confirmed, with 52.8 Gy (RBE) in 4 fractions established as the recommended treatment course for eligible HCC patients. Cancer 2017. © 2017 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. |
|||||
| 書誌情報 |
Cancer 巻 123, 号 20, p. 3955-3965, 発行日 2017-06 |
|||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 0008-543X | |||||
| PubMed番号 | ||||||
| 識別子タイプ | PMID | |||||
| 関連識別子 | 28662297 | |||||
| DOI | ||||||
| 識別子タイプ | DOI | |||||
| 関連識別子 | 10.1002/cncr.30816 | |||||
Share
Cite as
Kasuya, Goro, Katou, Hirotoshi, Yasuda, Shigeo, Tsuji, Hiroshi, Yamada, Shigeru, Haruyama, Yasuo, Kobashi, Gen, Ebner, Daniel, Okada, Naomi, Makishima, Hirokazu, Miyazaki, Masaru, Kamada, Tadashi, Tsujii, Hirohiko, 粕谷 吾朗, 加藤 博敏, 安田 茂雄, 辻 比呂志, 山田 滋, 春山 康夫, 小橋 元, エブナー ダニエル, 岡田 直美, 牧島 弘和, 宮崎 勝, 鎌田 正, 辻井 博彦, n.d., Progressive hypofractionated carbon-ion radiotherapy for hepatocellular carcinoma: Combined analyses of 2 prospective trials: 3955–3965 p.
Loading...
